Abiopharma

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

Net Asset Value(s)

Private placement of 430,835 to employees, officers and CEO

Financial Statements and Related Announcement: Full Yearly Results

FORM 6-K- Investor Presentation - June 2026

Martin Marietta to Combine with Lhoist North America in $13.5 Billion Transaction

Honeywell Aerospace completes spin-off from Honeywell Technologies and begins trading on Nasdaq

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

Compass Minerals Announces S&P Global Ratings Upgrade to B+

Keel Infrastructure Added to Russell 3000® Index